{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Machado P"],"funding":["Siemens Medical Solutions USA","NCI NIH HHS","National Institutes of Health","GE Healthcare"],"pagination":["616-625"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9943072"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["49(2)"],"pubmed_abstract":["The objective of the work described here was to evaluate the efficacy of lymphosonography in identifying sentinel lymph nodes (SLNs) in patients with breast cancer undergoing surgical excision. Of the 86 individuals enrolled, 79 completed this institutional review board-approved study. Participants received subcutaneous 1.0-mL injections of ultrasound contrast agent (UCA) around the tumor. An ultrasound scanner with contrast-enhanced ultrasound (CEUS) capabilities was used to identify SLNs. Participants were administered with blue dye and radioactive tracer to guide SLN excision as standard-of-care. Excised SLNs were classified as positive or negative for the presence of blue dye, radioactive tracer and UCA, and sent for pathology. Two hundred fifty-two SLNs were excised; 158 were positive"],"journal":["Ultrasound in medicine & biology"],"pubmed_title":["Sentinel Lymph Node Identification in Patients With Breast Cancer Using Lymphosonography."],"pmcid":["PMC9943072"],"funding_grant_id":["R01 CA172336"],"pubmed_authors":["Berger A","Needleman L","Lazar M","Willis AI","Nazarian S","Brill K","Forsberg F","Machado P","Liu JB"],"additional_accession":[]},"is_claimable":false,"name":"Sentinel Lymph Node Identification in Patients With Breast Cancer Using Lymphosonography.","description":"The objective of the work described here was to evaluate the efficacy of lymphosonography in identifying sentinel lymph nodes (SLNs) in patients with breast cancer undergoing surgical excision. Of the 86 individuals enrolled, 79 completed this institutional review board-approved study. Participants received subcutaneous 1.0-mL injections of ultrasound contrast agent (UCA) around the tumor. An ultrasound scanner with contrast-enhanced ultrasound (CEUS) capabilities was used to identify SLNs. Participants were administered with blue dye and radioactive tracer to guide SLN excision as standard-of-care. Excised SLNs were classified as positive or negative for the presence of blue dye, radioactive tracer and UCA, and sent for pathology. Two hundred fifty-two SLNs were excised; 158 were positive","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-26T11:54:47.786Z","creation":"2025-02-19T05:00:13.894Z"},"accession":"S-EPMC9943072","cross_references":{"pubmed":["36446688"],"doi":["10.1016/j.ultrasmedbio.2022.10.020"]}}